Stimulating effect of biologically modified low density lipoproteins on ADP-induced aggregation of washed platelets persists in absence of specific binding

Thrombosis Research

Volumn 97, Issue 6, 2000, Pages 441-449

  Volf, Ivo ^a   Roth, Astrid ^a   Moeslinger, Thomas ^a   Cooper, Julian ^a   Schmid, Werner ^a   Zehetgruber, Manfred ^b   Koller, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Oxidized LDL; Platelet aggregation; Platelets; Scavenger receptor

Indexed keywords

ADENOSINE DIPHOSPHATE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; LIPID OXIDATION; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE;

ADENOSINE DIPHOSPHATE; ANIMALS; BINDING, COMPETITIVE; BLOOD PLATELETS; CATTLE; CELL LINE; HUMANS; LIPOPROTEINS, LDL; PLATELET AGGREGATION; SERUM ALBUMIN, BOVINE; THROMBIN;

EID: 0033998397     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00197-8     Document Type: Article

References (40)

1. Bruckdorfer K.R. Oxidized lipoproteins. Baillieres Clin Endocrinol Metab. 9:1995;721-737.
2. Penn M.S., Chisolm G.M. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 108(Suppl):1994;S21-S29.
3. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
4. Berliner J.A., Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radical Biol Med. 20:1996;707-727.
5. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation. 86:1992;III95-III99.
6. Holvoet P., Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol. 8:1997;320-328.
7. Haberland M.E., Fong D., Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:1988;215-218.
8. Boyd H.C., Gown A.M., Wolfbauer G., Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol. 135:1989;815-825.
9. Rosenfeld M.E., Palinski W., Yla Herttuala S., Butler S., Witztum J.L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:1990;336-349.
10. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 268:1993;11811-11816.
11. Pedreno J., de Castellarnau C., Cullare C., Ortin R., Sanchez J.L., Llopart R., Gonzalez-Sastre F. Platelet LDL receptor recognizes with the same apparent affinity both oxidized and native LDL Evidence that the receptor-ligand complexes are not internalized. Arterioscler Thromb. 14:1994;401-408.
12. Koller E., Volf I., Mitterdorfer G., Kaar M., Koller F. Stimulation of human blood platelets by LDL. Differential effects of chemical modifications including oxidation Acta Angiologica. 2:1996;133-145.
13. Volf I., Moeslinger T., Cooper J., Schmid W., Koller E. Human platelets exclusively bind oxidized LDL showing no specificity for acetylated LDL. FEBS Lett. 449:1999;141-145.
14. Ardlie N.G., Selley M.L., Simons L.A. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis. 76:1989;117-124.
15. Chen L.Y., Mehta P., Mehta J.L. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets. Relevance of the effect of oxidized LDL on platelet function Circulation. 93:1996;1740-1746.
16. Minuz P., Lechi C., Gaino S., Bonapace S., Fontana L., Garbin U., Paluani F., Cominacini L., Zatti M., Lechi A. Oxidized LDL and reduction of the antiaggregating activity of nitric oxide derived from endothelial cells. Thromb Haemost. 74:1995;1175-1179.
17. Takahashi Y., Chiba H., Matsuno K., Akita H., Hui S.P., Nagasaka H., Nakamura H., Kobayashi K., Tandon N.N., Jamieson G.A. Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Biochem Biophys Res Commun. 222:1996;453-459.
18. Takahashi Y., Fuda H., Yanai H., Akita H., Shuping H., Chiba H., Matsuno K. Significance of membrane glycoproteins in platelet interaction with oxidized low-density lipoprotein. Semin Thromb Hemost. 24:1998;251-253.
19. Naseem K.M., Goodall A.H., Bruckdorfer K.R. Differential effects of native and oxidatively modified low density lipoproteins on platelet function. Platelets. 8:1997;163-173.
20. Weidtmann A., Scheithe R., Hrboticky N., Pietsch A., Lorenz R., Siess W. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler Thromb Vasc Biol. 15:1995;1131-1138.
21. Butler P.J.G., Hartley B.S. Maleylation of amino groups. Methods Enzmol. 25:1972;191-199.
22. Noble R.P. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res. 9:1968;693-700.
23. Mihara M., Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 86:1978;271-278.
24. El-Saadani M., Esterbauer H., El-Sayed M., Goher M., Nassar A.Y., Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 30:1989;627-630.
25. Koller E., Koller F. Binding characteristics of homologous plasma lipoproteins to human platelets. Methods Enzymol. 215:1992;383-398.
26. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1353.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
28. Enenstein J., Gupta K., Vercellotti G.M., Hebbel R.P. Thrombin-stimulated calcium mobilization is inhibited by thrombospondin via CD36. Exp Cell Res. 238:1998;465-471.
29. Zhao B., Dierichs R., Miller F.N., Dean W.L. Oxidized low density lipoprotein inhibits platelet plasma membrane Ca(2+)-ATPase. Cell Calcium. 19:1996;453-458.
30. Zhao B., Dierichs R., Liu B., Holling-Raub M. Functional morphological alterations of human blood platelets induced by oxidized low density lipoprotein. Thromb Res. 74:1994;293-301.
31. Krieger M., Herz J. Structures and functions of multiligand lipoprotein receptors. Macrophage scavenger receptors and LDL receptor-related protein (LRP) Annu Rev Biochem. 63:1994;601-637.
32. Pearson A.M. Scavenger receptors in innate immunity. Curr Opin Immunol. 8:1996;20-28.
33. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr. 57(Suppl 5):1993;779S-785S.
34. Benveniste J., Le Couedic J.P., Kamoun P. Aggregation of human platelets by platelet-activating factor. Lancet. 1:1975;344-345.
35. Morrow J.D., Minton T.A., Roberts L.J. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 44:1992;155-163.
36. Mehta J.L., Chen L.Y. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J Lab Clin Med. 127:1996;287-295.
37. Aviram M. Modified forms of low density lipoprotein affect platelet aggregation in vitro. Thromb Res. 53:1989;561-567.
38. Thomas C.E., Jackson R.L., Ohlweiler D.F., Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res. 35:1994;417-427.
39. Korotaeva A.A., Cheglakov I.B., Prokazova N.V. Inhibitory effect of lysophosphatidylcholine and phospholipase A-2-treated low density lipoproteins on receptor-dependent regulation of [Ca(2+)](i) in platelets. Platelets. 8:1997;43-51.
40. Yuan Y., Jackson S.P., Newnham H.H., Mitchell C.A., Salem H.H. An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Blood. 86:1995;4166-4174.